The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: Implications for future care in the age of increasing antiretroviral resistance

Critical Care Medicine

Volumn 29, Issue 3, 2001, Pages 548-556

  Rosenberg, Andrew L ^a   Seneff, Michael G ^b   Atiyeh, Lyna ^b   Wagner, Randall ^b   Bojanowski, Leody ^b   Zimmerman, Jack E ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acquired immunodeficiency syndrome; Acute Physiology and Chronic Health Evaluation; Bacterial infection; Human immunodeficiency virus; Intensive care unit; Patient outcomes; Sepsis; Severity of illness; Systemic inflammatory response syndrome

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 0035103402     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200103000-00013     Document Type: Article

References (86)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Decline in deaths from AIDS due to new antiretrovirals
3. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
4. Outcome of intensive care in patients with the acquired immunodeficiency syndrome
5. Intensive care of patients with the acquired immunodeficiency syndrome: Outcome and changing patterns of utilization
6. AIDS in ICU's: Outcome
7. Admission of AIDS patients to a medical intensive care unit: Causes and outcome
8. Differential survival of patients with AIDS according to the 1987 and 1993 CDC case definitions
9. Prognosis of patients with AIDS requiring intensive care
10. Intensive care unit patients with immunodeficiency syndrome and Pneumocystis carinii pneumonia: Suggested predictors of hospital outcome
11. Critical care of patient with AIDS
12. Outcome of intensive care in patients with HIV infection
13. AIDS in a medical intensive care unit immediate prognosis and long-term survival
14. Intensive care of patients with HIV infection utilization, critical illnesses, and outcomes
15. Results of TRILEGE trial, a comparison of three maintenance regimens for HIV infected adults receiving induction therapy with zidovudine, lamivudine, and indinavir
16. Randomized trial of indinavir vs zidovudine, lamivudine vs indinavir/zidovudine/lamivudine maintenance therapy after induction of indinavir/zidovudine/lamivudine therapy
17. Do dual nucleoside regimens have a role in an era of plasma viral load-driven antiretroviral therapy?
18. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
19. Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women
20. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
21. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
22. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
23. Viral dynamics in HIV-1 infection
24. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
25. CD4-cell count in HIV-1 infected individuals remaining viremic with highly active antiretroviral therapy (HAART), Swiss HIV Cohort Study
26. Induction/maintenance treatment regimens for HIV
27. Antiretroviral drug resistance testing in HIV infection of adults: Implications for clinical management
28. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
29. Visceral abdominal-fat accumulation associated with use of indinavir
30. A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance due to HIV protease inhibitors (PIs)
31. Infectious Diseases in the ICU
32. Pulmonary complications of the acquired immunodeficiency syndrome: Report of a national heart lung and blood institute workshop
33. Outcomes of intensive care for patients with human immunodeficiency virus infection
34. Predictive ability of Acute Physiology and Chronic Health Evaluation II scoring applied to human immunodeficiency virus-positive patients
35. Septic shock in patients with the acquired immunodeficiency syndrome
36. Bacterial pneumonia in persons infected with the human immunodeficiency virus: Pulmonary Complications of HIV Infection Study Group
37. Bacteremia and fungemia in patients with the acquired immunodeficiency syndrome
38. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex
39. Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease
40. The APACHE III prognostic system: Risk prediction of hospital mortality for critically ill hospitalized adults
41. Reliability of a measure of severity of illness: Acute Physiology and Chronic Health Evaluation-II
42. Severity measurement and efficacy of nutritional support: Neither success nor failure
43. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
44. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
45. Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients
46. Bilateral bronchoalveolar lavage in the diagnosis of opportunistic pulmonary infections
47. A controlled trial of scheduled replacement of central venous and pulmonary artery catheters
48. A comparison of goodness-of-fit tests for the logistic regression model
49. Survival for women and men with AIDS
50. The effects on survival of early treatment of human immunodeficiency virus infection
51. Evolving trends revealed by autopsies of patients with the acquired immunodeficiency syndrome
52. Bacterial pneumonia in patients with human immunodeficiency virus infection
53. Septicemia in patients with AIDS
54. Clinical manifestation of AIDS in the era of Pneumocystis prophylaxis
55. Pneumocystis carinii pneumonia and respiratory failure in AIDS: Improved outcomes and increased use of intensive care units
56. Prevention and treatment of Pneumocystis pneumonia
57. Acute respiratory failure secondary to Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A potential role for systemic corticosteroids
58. Long-term survival of patients with AIDS, Pneumocystis carinii pneumonia, and respiratory failure
59. Mechanical ventilation for Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: Is the prognosis really improved?
60. Zidovudine and the natural history of the acquired immunodeficiency syndrome
61. Community-acquired bacteremia in HIV-positive patients: Protective benefit of co-trimoxazole
62. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure
63. The changing spectrum of pulmonary complications of HIV infection
64. Pseudomonas aeruginosa bacteremia in patients with AIDS
65. Bacterial infections in the acquired immunodeficiency syndrome
66. Bacterial and fungal infections in patients with the acquired immunodeficiency syndrome
67. Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS
68. Autoimmune neutropenia and thrombocytopenia associated with development of antibodies to human immunodeficiency virus
69. Vancomycin and neutropenia in AZT-treated AIDS patients with staphylococcal infections
70. Prevention of bacterial infections in patients with advanced HIV infection
71. Validation of HIV-1 RNA and CD4 count as surrogate markers in the CAESAR trial
72. Severe Pneumocystis carinii pneumonia produces a hyperdynamic profile similar to bacterial pneumonia with sepsis
73. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection
74. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter, controlled trial
75. Neutropenia associated with oral acyclovir and multiple antibacterial agents in a patient with acquired immunodeficiency syndrome
76. Leads from the MMWR: Severe neutropenia during pentamidine treatment of Pneumocystis carinii pneumonia in patients with AIDS
77. Lithium carbonate therapy for zidovudine-associated neutropenia in patients with acquired immunodeficiency syndrome
78. Nosocomial pneumonia in intensive care units
79. Predictors of duration of plasma viral load suppression
80. Detection of nosocomial lung infection in ventilated patients: Use of a protected specimen brush and quantitative culture techniques in 147 patients
81. Influence of pulmonary bacteriology and histology on the yield of diagnostic procedures in ventilator-acquired pneumonia
82. Bronchoscopy specimens in adults with AIDS
83. Diagnostic tests for pneumonia in ventilated patients: Prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard
84. Pulmonary manifestations of Kaposi's sarcoma
85. Presentation of AIDS-related Kaposi's sarcoma diagnosed by bronchoscopy
86. The pulmonary manifestations of AIDS-related non-Hodgkin's lymphoma